 SPARTA, N.J., Oct. 26, 2022 GLOBE NEWSWIRE -- PLx Pharma Inc. NASDAQ: PLXP PLx or the Company is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuardTM that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules referred to together as VAZALORE, today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. 